Smith & Nephew Plc Stock BOERSE MUENCHEN

Equities

NPW1

GB0009223206

Medical Equipment, Supplies & Distribution

Real-time BOERSE MUENCHEN 11:43:52 2024-05-16 EDT 5-day change 1st Jan Change
12 EUR 0.00% Intraday chart for Smith & Nephew Plc +2.48% -2.83%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 5.82B 5.35B 7.92B Sales 2025 * 6.12B 5.63B 8.33B Capitalization 11.27B 10.36B 15.33B
Net income 2024 * 541M 497M 736M Net income 2025 * 694M 638M 944M EV / Sales 2024 * 2.38 x
Net Debt 2024 * 2.56B 2.35B 3.48B Net Debt 2025 * 2.23B 2.05B 3.03B EV / Sales 2025 * 2.21 x
P/E ratio 2024 *
21.9 x
P/E ratio 2025 *
16.8 x
Employees -
Yield 2024 *
2.96%
Yield 2025 *
3.32%
Free-Float 99.15%
More Fundamentals * Assessed data
Dynamic Chart
1 week+2.48%
Current month+3.58%
1 month+4.99%
3 months-7.69%
6 months+0.42%
Current year-2.83%
More quotes
1 week
11.71
Extreme 11.71
12.00
1 month
11.15
Extreme 11.15
12.00
3 years
10.38
Extreme 10.375
18.81
5 years
10.38
Extreme 10.375
23.83
More quotes
Managers TitleAgeSince
Chief Executive Officer - 22-03-31
Director of Finance/CFO 56 11-30
Compliance Officer - 99-03-31
Members of the board TitleAgeSince
Director/Board Member 65 17-09-30
Director/Board Member 62 23-09-13
Chairman 63 23-04-25
More insiders
Date Price Change
24-05-16 12 0.00%
24-05-15 12 +1.22%
24-05-14 11.86 +0.25%
24-05-13 11.82 0.00%
24-05-10 11.82 -0.30%

Real-time BOERSE MUENCHEN, May 16, 2024 at 11:43 am

More quotes
Smith & Nephew Plc specializes in designing, manufacturing and marketing medical products and equipment. Net sales break down by activity sector as follows: - orthopedic surgery (39.9%): primarily orthopedic implants (hips, knees and shoulders); - sports medicine, arthroscopy and cervicofacial surgery (31.2%): surgery and damaged tissue repair products and instruments, visualization products, etc.; - wound care (28.9%): skin grafts for major burns victims, treatments for leg ulcers, etc. The United States accounts for 53.7% of net sales.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
12.92 USD
Average target price
16.35 USD
Spread / Average Target
+26.49%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW